How do I perform cell salvage in obstetrics?

Waters, Jonathan H.; Beck, Stacy; Yazer, Mark H.

doi:10.1111/trf.15352

Cited by 15 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 17–19 ] In summary, the primary and indispensable cryopreservation science for various biological samples (e.g., cells, tissues, organs, and vaccines) is vital for clinical applications and scientific research in the field of biomedical engineering. [ 20–24 ]…”

Section: Introductionmentioning

confidence: 99%

Ice Inhibition for Cryopreservation: Materials, Strategies, and Challenges

2021

View full text Add to dashboard Cite

Cryopreservation technology has developed into a fundamental and important supporting method for biomedical applications such as cell‐based therapeutics, tissue engineering, assisted reproduction, and vaccine storage. The formation, growth, and recrystallization of ice crystals are the major limitations in cell/tissue/organ cryopreservation, and cause fatal cryoinjury to cryopreserved biological samples. Flourishing anti‐icing materials and strategies can effectively regulate and suppress ice crystals, thus reducing ice damage and promoting cryopreservation efficiency. This review first describes the basic ice cryodamage mechanisms in the cryopreservation process. The recent development of chemical ice‐inhibition molecules, including cryoprotectant, antifreeze protein, synthetic polymer, nanomaterial, and hydrogel, and their applications in cryopreservation are summarized. The advanced engineering strategies, including trehalose delivery, cell encapsulation, and bioinspired structure design for ice inhibition, are further discussed. Furthermore, external physical field technologies used for inhibiting ice crystals in both the cooling and thawing processes are systematically reviewed. Finally, the current challenges and future perspectives in the field of ice inhibition for high‐efficiency cryopreservation are proposed.

show abstract

Section: Introductionmentioning

confidence: 99%

Ice Inhibition for Cryopreservation: Materials, Strategies, and Challenges

2021

View full text Add to dashboard Cite

show abstract

“…Existing protocols for the collection and processing of blood in obstetrics are well documented and directed toward intraoperative blood collection during cesarean section. 2,10 Current protocols, however, do not address the specific challenges of vaginal blood collection, such as a mechanism to separate blood from amniotic fluid, or space and proximity barriers to access cell salvage equipment immediately in the delivery room. In our study, we observed that patients with severe hemorrhage following vaginal delivery are often moved to the operating room for management.…”

Section: Discussionmentioning

confidence: 99%

“…An area of particular interest includes cases with large QBL but a low volume of recovered blood and a low volume of autologous product transfused to the patient. Existing protocols for the collection and processing of blood in obstetrics are well documented and directed toward intraoperative blood collection during cesarean section 2,10 . Current protocols, however, do not address the specific challenges of vaginal blood collection, such as a mechanism to separate blood from amniotic fluid, or space and proximity barriers to access cell salvage equipment immediately in the delivery room.…”

Section: Discussionmentioning

confidence: 99%

“…Autotransfusion, also known as cell salvage, is the process of blood collection, processing, and re‐administration during hemorrhage 1,2 . Historically, utilization of cell salvage technology for obstetric hemorrhage has been controversial due to concern for contamination with amniotic fluid and fetal cells 3,4 .…”

Section: Introductionmentioning

confidence: 99%

“…during hemorrhage. 1,2 Historically, utilization of cell salvage technology for obstetric hemorrhage has been controversial due to concern for contamination with amniotic fluid and fetal cells. 3,4 Autotransfusion has since gained acceptance as a safe and effective tool for the management of intraoperative hemorrhage during cesarean delivery.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Autotransfusion of vaginally shed blood as a novel therapy in obstetric hemorrhage: A case series

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective To report maternal outcomes in a cohort of women who received autotransfusion of vaginally shed blood and to describe the feasibility of blood collection and cell salvage processing at the time of vaginal hemorrhage. Study Design and Methods We conducted a retrospective case series of patients who received autotransfusion of vaginally shed blood at the time of obstetric hemorrhage from January 2014 to August 2020. Maternal data and cell salvage utilization characteristics were abstracted from the electronic medical record. Results Sixty‐four cases were identified in which autotransfusion of vaginally shed blood occurred during an obstetric hemorrhage. Median quantitative blood loss was 2175 ml (interquartile range 1500–2250 ml) with 89% of cases having a blood loss greater than 1000 ml. Patients on average received approximately 1.3 units of autologous blood product (384 ml, interquartile range 244–520 ml) and no direct adverse events were observed during transfusion. We observed heterogeneity in autologous blood volume across all values of quantitative blood loss. The need for allogenic blood transfusion was common and occurred in 72% of all cases (N = 46). There were no documented cases of maternal sepsis or severe infectious morbidity. Conclusion In 64 cases where autotransfusion of vaginally shed blood occurred, autotransfusion was well tolerated. Heterogeneity in autologous blood volume collection likely represents the lack of standardized protocols for blood collection in the delivery room. Autotransfusion of vaginally shed blood is a feasible and reasonable technique to employ during severe obstetric hemorrhage.

show abstract